A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910